<DOC>
	<DOCNO>NCT01763905</DOCNO>
	<brief_summary>The primary objective evaluate effect 12 week subcutaneous ( SC ) evolocumab every 2 week ( Q2W ) monthly ( QM ) , compare ezetimibe , percent change baseline low-density lipoprotein cholesterol ( LDL-C ) hypercholesterolemic adult unable tolerate effective dose statin ( HMG-CoA ( 5-hydroxy-3-methylglutaryl-coenzyme A ) reductase inhibitor ) .</brief_summary>
	<brief_title>Goal Achievement After Utilizing Anti-PCSK9 Antibody Statin Intolerant Subjects -2</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male female ≥ 18 ≤ 80 year age Not statin low dose statin stable dose least 4 week History intolerance least 2 statin Subject LDLC goal Lipid lower therapy stable prior enrolment least 4 week . Fasting triglyceride ≤ 400 mg/dL New York Heart Association ( NYHA ) III IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension Type 1 diabetes , poorly control type 2 diabetes Uncontrolled hypothyroidism hyperthyroidism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>High Cholesterol , Treatment high cholesterol , Lowering cholesterol , Lowering high cholesterol , Hypercholesterolemia</keyword>
</DOC>